US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Neuroscience and Healthcare ETF

38.96

-0.2700-0.69%

Post-market: 39.230.2700+0.69%16:10 EDT

Volume:279

Turnover:10.81K

Market Cap:7.79M

PE:- -

High:38.96

Open:39.22

Low:38.96

Close:39.23

52wk High:43.01

52wk Low:24.96

Shares:200.00K

Float Shares:200.00K

Volume Ratio:0.12

T/O Rate:0.14%

Dividend:0.32

Dividend Rate:0.83%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Xenon Pharmaceuticals Q2 Operating Expenses USD 123.155 Million

THOMSON REUTERS

Xenon Pharmaceuticals - Anticipates Sufficient Cash to Fund Operations into 2029

THOMSON REUTERS

Xenon Reports Q2 2026 Financial Results and Provides Business Update

THOMSON REUTERS

The Race to Come up with the Next Big Sleep Drug

Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA), Privia Health Group (PRVA) and Praxis Precision Medicines (PRAX)

Praxis Precision Medicines, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Scholar Rock Holding Corporation Reports Results for the Quarter Ended June 30 - Earnings Summary

Praxis Q2 2026 results: $1.4 billion liquidity supports runway into 2028

Scholar Rock Files for up to $200 Million At-the-Market Stock Offering

Praxis Precision Medicines Posts Investor Deck Highlighting Late-Stage CNS Pipeline, Upcoming PDUFA Dates

Praxis Precision Q2 Net Loss Widens on Higher Expenses

Praxis Precision Net Loss Widens 17.7% to $83.72 Million in Q2 FY26

Praxis Precision Medicine Q2 EPS $(2.87) Beats $(3.65) Estimate

Benzinga Earnings

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results

THOMSON REUTERS

Praxis Precision Q2 EPS USD -2.87

THOMSON REUTERS

Praxis Precision Q2 Operating Expenses USD 96.904 Million

THOMSON REUTERS

Viridian Therapeutics Q2 Net Loss Widens as Lumvoa Launch Lifts Costs

Climb Bio Q2 Net Loss Widens on Pipeline Advancement

Scholar Rock Q2 Net Loss Narrows

Scholar Rock Holding Q2 EPS $(0.84) Beats $(0.85) Estimate; Cash Balance Of $492M

Benzinga Earnings

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/IBRN/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBRN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","market":"US","secType":"STK","nameCN":"iShares Neuroscience and Healthcare ETF","latestPrice":38.9601,"timestamp":1788206400000,"preClose":39.2301,"halted":0,"volume":279,"hourTrading":{"tag":"盘后","latestPrice":39.2301,"preClose":38.9601,"latestTime":"16:10 EDT","volume":7,"amount":272.7207,"timestamp":1788207004390,"change":0.27,"changeRate":0.00693,"amplitude":0},"delay":0,"changeRate":-0.006882470348023664,"floatShares":200000,"shares":200000,"eps":0,"marketStatus":"Not Yet Opened","change":-0.27,"latestTime":"08-31 16:00:00 EDT","open":39.22,"high":38.9601,"low":38.9601,"amount":10811,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788249600000},"marketStatusCode":0,"adr":0,"exchange":"ARCA","adjPreClose":39.2301,"sharesOutstanding":150000,"nav":39.171708,"aum":7834341.6,"dividendRate":0.008257,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":39.2301,"preClose":38.9601,"latestTime":"16:10 EDT","volume":7,"amount":272.7207,"timestamp":1788207004390,"change":0.27,"changeRate":0.00693,"amplitude":0},"volumeRatio":0.121537,"impliedVol":0.124,"impliedVolPercentile":0.6653},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","floatShares":200000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.121537,"shares":200000,"dividePrice":0.3217,"high":38.9601,"amplitude":0,"preClose":39.2301,"low":38.9601,"week52Low":24.9594,"pbRate":"--","week52High":43.01,"institutionHeld":0,"latestPrice":38.9601,"eps":0,"divideRate":0.008257,"volume":279,"delay":0,"ttmEps":0,"open":39.22,"prevYearClose":32.3193,"prevWeekClose":39.2301,"prevMonthClose":36.6044,"prevQuarterClose":38.8263,"fiveDayClose":39.5297,"twentyDayClose":36.6969,"sixtyDayClose":34.9273},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBRN\",params:#limit:5,,,undefined,":[{"date":"2025-12-16","symbol":"IBRN","amount":0.319807,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2024-12-17","symbol":"IBRN","amount":0.10114,"announcedDate":"2024-12-16","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2023-12-20","symbol":"IBRN","amount":0.006303,"announcedDate":"2023-12-19","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"},{"date":"2023-06-07","symbol":"IBRN","amount":0.008241,"announcedDate":"2023-05-12","type":"dividend","market":"US","newRecordDate":"2023-06-08","defaultRemindTime":1686144600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-06-13","payableDate":"2023-06-08","currency":"USD","dateTimestamp":1686110400000,"payDate":"2023-06-13"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBRN\",market:\"US\",,,undefined,":[{"executeDate":"2023-06-07","recordDate":"2023-06-08","paymentDate":"2023-06-13","value":0.008241,"currency":"USD"},{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-27","value":0.006303,"currency":"USD"},{"executeDate":"2024-12-17","recordDate":"2024-12-17","paymentDate":"2024-12-20","value":0.10114,"currency":"USD"},{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-19","value":0.319807,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBRN\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBRN\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657652480","title":"Xenon Pharmaceuticals Q2 Operating Expenses USD 123.155 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657652480","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657652480?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:01","pubTimestamp":1786046461,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXHL9M8F:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SBIO","IBRN","BK4139","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657521606","title":"Xenon Pharmaceuticals - Anticipates Sufficient Cash to Fund Operations into 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2657521606","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657521606?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:01","pubTimestamp":1786046461,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXHL9M8F:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SBIO","IBRN","XENE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657465223","title":"Xenon Reports Q2 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2657465223","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657465223?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:01","pubTimestamp":1786046461,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUA4YCGCT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XENE","IBRN","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657651052","title":"The Race to Come up with the Next Big Sleep Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2657651052","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657651052?lang=en_us&edition=fundamental","pubTime":"2026-08-07 02:30","pubTimestamp":1786041000,"startTime":"0","endTime":"0","summary":"Narcolepsy isn't easy to treat. Existing drugs manage patients' symptoms -- notably excessive daytime sleepiness and difficulty sleeping at night -- rather than the cause. Yet a new type of drug is em","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014906.USD","SG9999014898.SGD","LU0256863811.USD","LU0266013472.USD","LU1623119135.USD","LU2237443465.HKD","LU2552382058.USD","LU2237438978.USD","LU0122379950.USD","LU0198837287.USD","BK4139","LU2896262040.SGD","LU2265009873.SGD","LU1917777945.USD","LU1323610961.USD","IE0001KFT4U8.USD","LU0316494557.USD","LU2756315318.SGD","LU0417517546.SGD","LU1868837300.USD","LU2750360641.GBP","IE0002141913.USD","LU2756315664.SGD","IE00B2B36J28.USD","LU0471298777.SGD","LU0640476718.USD","LU2023250330.USD","LU2471134796.USD","LU2750360997.AUD","VHT","LLY","LU0203202063.USD","LU2023251221.USD","BK4581","LU1868836591.USD","LU2357305700.SGD","LU1035775433.USD","SGXZ99366536.SGD","LU2324357040.USD","LU2271345857.HKD","ILDR","LU0353189763.USD","LU0820561818.USD","LU0786609619.USD","LU0820561909.HKD","LU1983299246.USD","LU2462157665.USD","LU0354030511.USD","LU2063271972.USD","LU0203201768.USD","TRUH","LU0323591593.USD","TMED","LU1061106388.HKD","IE00BJLML261.HKD","LU2264538146.SGD","CANC","SG9999001176.USD","LU0234572021.USD","LU0354030438.USD","BK4599","LU0882574055.USD","LU1057294990.SGD","LU2028103732.USD","IE0004445239.USD","LU1291159041.SGD","LU1720051108.HKD","FBT","LU1551013425.SGD","ELIL","LU0210536198.USD","LU0353189680.USD","LU2213496289.HKD","LU1974910355.USD","SGXZ57979304.SGD","JDOC","LU0889565916.HKD","BK4007","LU2236285917.USD","LU2168564065.EUR","LU2089984988.USD","IE0009355771.USD","LU0823434583.USD","LLII","ELIS","LU2112291526.USD","LU0058720904.USD","LU0466842654.USD","LLYZ","LU1989771016.USD","LU2168563687.JPY","LU2471134523.USD","LU2361045086.USD","LU2237443549.SGD","LU2211815571.USD","IE00BWXC8680.SGD","LU2361044865.SGD","LU0385154629.USD","LU0320765992.SGD","LU1093756325.SGD","LU2106854487.HKD","LU2237443382.USD","LU2602419157.SGD","LU0158827948.USD","GB00BDT5M118.USD","PJP","LU0672654240.SGD","LU2552382215.SGD","SG9999001176.SGD","LU0094547139.USD","LU0345770993.USD","LU0456855351.SGD","IE00B4JS1V06.HKD","IE00BK4W5M84.HKD","IE00BJT1NW94.SGD","IE00BKDWB100.SGD","LLYX","LU2168564149.EUR","LU0882574139.USD","MEDX","IXJ","LU0943347566.SGD","LU2108987350.USD","HRTS","LU0787776722.HKD","SG9999013999.USD","IE00B7KXQ091.USD","LU1267930730.SGD","LU2491050154.USD","BK4588","IE0004445015.USD","IHE","LU2491049909.HKD","IE00BN29S564.USD","LU2089283258.USD","LU0345770308.USD","FTXH","LU2461242641.AUD","SG9999014880.SGD","IE0005OL40V9.USD","LU2168564495.EUR","SG9999015978.USD","SGXZ31699556.SGD","LU1232071149.USD","LU2089284900.SGD","BK4516","LU0289739699.SGD","SGXZ81514606.USD","LU2237443622.USD","IE00B775H168.HKD","LU2111349929.HKD","PSCH","LU2168564222.USD","LU2360106947.USD","LU1988902786.USD","SG9999014914.USD","LU0109391861.USD","LU2471134879.HKD","IYH","SG9999017495.SGD","LU1127390331.HKD","LU0006306889.USD","LU0225283273.USD","LU2462591350.SGD","LU2491050071.SGD","LU1145028129.USD","BK4534","LU0133085943.USD","BK4585","LU1280957306.USD","LU1814569148.SGD","OZEM","LU2361044949.HKD","RXL","WDNA","LU0823434740.USD","IE00BFSS7M15.SGD","LU0096364046.USD","LU1868836757.USD","LU1366192091.USD","IE00B4R5TH58.HKD","SGXZ51526630.SGD","LU1093756168.USD","IE00BFSS8Q28.SGD","IE00BJJMRY28.SGD","SG9999015986.USD","PSIL","SG9999018865.SGD","LU0683600562.USD","LU0820562030.AUD","LU2746668461.USD","LU0471298694.HKD","LU1629891620.HKD","LU1868837136.USD","GDOC","ALKS","LU0432979614.USD","LU0174119429.USD","LU1551013342.USD","LU2237443978.SGD","LU2023250504.SGD","LU0109394709.USD","LU0320765059.SGD","LU0689472784.USD","IE00B1BXHZ80.USD","LU0114720955.EUR","SG9999015952.SGD","IBRN","LU0097036916.USD","LU0238689110.USD","LU0964807845.USD","IE00BFTCPJ56.SGD","LU1064131342.USD","CURE","LU0106261372.USD","LU2746668974.SGD","FHLC","IE00B1XK9C88.USD","IE00BJJMRX11.SGD","THNR","SG9999015945.SGD","AGNG","MEDI","LU2417539215.USD","LU1712237335.SGD","PPH","LU2468319806.SGD","LU0823416689.USD","IE00BK4W5L77.USD","LU0061475181.USD","TAK","LU1023059063.AUD","LU1804176565.USD","LU2237443895.HKD","LU2456880835.USD","LU1868836914.USD","LU0158827781.USD","LU0256863902.USD","IE00BJJMRZ35.SGD","LU2471134952.CNY","LU2087625088.SGD","LU1548497426.USD","MHIP","LU1979441026.SGD","XLV","LU1720051017.SGD","LU0708995401.HKD","BK4533","IE00BKPKM429.USD","LU1069344957.HKD","SG9999018857.SGD","LU2552382132.HKD","LU0079474960.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657651400","title":"Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA), Privia Health Group (PRVA) and Praxis Precision Medicines (PRAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657651400","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657651400?lang=en_us&edition=fundamental","pubTime":"2026-08-07 01:50","pubTimestamp":1786038610,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Tenaya Therapeutics (TNYA), Privia Health Group (PRV...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-tenaya-therapeutics-tnya-privia-health-group-prva-and-praxis-precision-medicines-prax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-tenaya-therapeutics-tnya-privia-health-group-prva-and-praxis-precision-medicines-prax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBRN","PRVA","TNYA","HCSG","BK4581","BK4139","IE00BFTCPJ56.SGD","LABU","LU0109394709.USD","XLV","IE00BJT1NW94.SGD","LU0889565916.HKD","BK4588","LU0029874061.USD","PRAX","BK4196","BK4137","IE00B2B36J28.USD","IE00B4R5TH58.HKD","BK4585","LU0320765992.SGD","BK4539","XBI","IE0009355771.USD","IE0002141913.USD","LU0128526141.USD","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657163708","title":"Praxis Precision Medicines, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657163708","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657163708?lang=en_us&edition=fundamental","pubTime":"2026-08-06 22:07","pubTimestamp":1786025274,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines, Inc. reports results for the quarter ended June 30 - Earnings SummaryPraxis Precision Medicines, Inc.PRAX.OQreported a quarterly adjusted loss of $2.87 per share for the qu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N44326M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX","LU0109394709.USD","IE00B2B36J28.USD","LU0889565916.HKD","IE0009355771.USD","BK4139","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","IBRN","IE0002141913.USD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657321716","title":"Scholar Rock Holding Corporation Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657321716","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657321716?lang=en_us&edition=fundamental","pubTime":"2026-08-06 21:31","pubTimestamp":1786023115,"startTime":"0","endTime":"0","summary":"Scholar Rock Holding Corporation reports results for the quarter ended June 30 - Earnings SummaryScholar Rock Holding CorporationSRRK.OQreported a quarterly adjusted loss of 84 cents per share for the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4431VG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBRN","SRRK","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657111634","title":"Praxis Q2 2026 results: $1.4 billion liquidity supports runway into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2657111634","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657111634?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:53","pubTimestamp":1786020784,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines’ Q2 2026 results showed a net loss of $83.7 million, up from $71.1 million a year earlier, while diluted loss per share narrowed to $2.87 from $3.31 because the weighted-average share count increased. R&D expense rose to $69.4 million and G&A expense more than doubled to $27.5 million. Cash, cash equivalents and marketable securities totaled approximately $1.4 billion at June 30, supporting operations into 2028 as Praxis prepares for regulatory decisions on relutrigine and ulixacaltamide and advances key epilepsy studies.","market":"sh","thumbnail":"https://resource.tradingkey.com/cdn/images/article/news/stock10.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cdn/images/article/news/stock10.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/earnings/262084149-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRAX","IE0002141913.USD","BK4588","IE00B2B36J28.USD","LABU","LU0889565916.HKD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","LU0109394709.USD","BK4139","IBRN","IE0009355771.USD","IE00BJJMRZ35.SGD","LU0320765992.SGD","IE00B4R5TH58.HKD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657863176","title":"Scholar Rock Files for up to $200 Million At-the-Market Stock Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2657863176","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657863176?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:50","pubTimestamp":1786020621,"startTime":"0","endTime":"0","summary":"Scholar Rock files for up to $200 million at-the-market stock offeringScholar Rock launched a refreshed at-the-market equity program to sell up to USD 200 million of common stock through Jefferies.The","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDLMYqCd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SRRK","BK4139","THNR","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657696631","title":"Praxis Precision Medicines Posts Investor Deck Highlighting Late-Stage CNS Pipeline, Upcoming PDUFA Dates","url":"https://stock-news.laohu8.com/highlight/detail?id=2657696631","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657696631?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:37","pubTimestamp":1786019853,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines posts investor deck highlighting late-stage CNS pipeline, upcoming PDUFA datesPraxis Precision Medicines highlighted four late-stage CNS programs, citing portfolio peak sale","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL9lM7CK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","LU0889565916.HKD","PRAX","IE00BJT1NW94.SGD","IE0009355771.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","BK4139","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU0320765992.SGD","LU0109394709.USD","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657395516","title":"Praxis Precision Q2 Net Loss Widens on Higher Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2657395516","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657395516?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:12","pubTimestamp":1786018371,"startTime":"0","endTime":"0","summary":"Praxis Precision Q2 net loss widens on higher expensesOverviewUS CNS drug developer's Q2 net loss widened yr/yr on higher operating expensesCompany ended Q2 with $1.4 bln in cash and investments, fund","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430NP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IBRN","PSIL","LU0889565916.HKD","IE00BJJMRZ35.SGD","IE0002141913.USD","PRAX","LU0320765992.SGD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","BK4139","IE00BJT1NW94.SGD","BK4539","HRMY","IE0009355771.USD","GHRS","LU0109394709.USD","VNDA","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657398376","title":"Praxis Precision Net Loss Widens 17.7% to $83.72 Million in Q2 FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2657398376","media":"Reuters","labels":["corporation","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657398376?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:08","pubTimestamp":1786018121,"startTime":"0","endTime":"0","summary":"Praxis Precision net loss widens 17.7% to $83.72 million in Q2 FY26Praxis Precision Medicines posted a Q2 GAAP net loss of USD 83.7 million, widening from USD 71.1 million a year earlier.R&D expenses rose 10.16% to USD 69.4 million, driven by higher Solidus spending and personnel costs, partly offset by lower Cerebrum expenses.G&A costs more than doubled to USD 27.5 million, on higher professional fees and personnel-related expenses.Cash, cash equivalents and marketable securities totaled USD 1.4 billion at June 30, extending the expected operating runway into 2028.FDA mid-cycle reviews flagged no major safety or efficacy issues for ulixacaltamide  or relutrigine .Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis Precision Medicine","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL9blbZs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","BK4139","IE0002141913.USD","IBRN","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","IE0009355771.USD","LU0109394709.USD","IE00BJJMRZ35.SGD","PRAX","IE00B2B36J28.USD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657636437","title":"Praxis Precision Medicine Q2 EPS $(2.87) Beats $(3.65) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657636437","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657636437?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:03","pubTimestamp":1786017826,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicine (NASDAQ:PRAX) reported quarterly losses of $(2.87) per share which beat the analyst consensus estimate of $(3.65) by 21.37 percent. This is a 13.29 percent increase over losses of $(3.31) per","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60991365/praxis-precision-medicine-q2-eps-2-87-beats-3-65-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJT1NW94.SGD","IBRN","IE00B4R5TH58.HKD","IE0009355771.USD","IE00BFTCPJ56.SGD","BK4139","PRAX","LU0109394709.USD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","LU0320765992.SGD","LU0889565916.HKD","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657863669","title":"Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2657863669","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657863669?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:00","pubTimestamp":1786017605,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUAB8QH5L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","LU0320765992.SGD","IE00BJJMRZ35.SGD","IE0002141913.USD","IE0009355771.USD","LU0109394709.USD","BK4139","PRAX","LU0889565916.HKD","IBRN","IE00BFTCPJ56.SGD","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657636569","title":"Praxis Precision Q2 EPS USD -2.87","url":"https://stock-news.laohu8.com/highlight/detail?id=2657636569","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657636569?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:00","pubTimestamp":1786017602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLX4G8G05:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0109394709.USD","LU0320765992.SGD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","IE0002141913.USD","IE00BFTCPJ56.SGD","PRAX","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","IE0009355771.USD","IBRN","LU0889565916.HKD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657366906","title":"Praxis Precision Q2 Operating Expenses USD 96.904 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657366906","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657366906?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:00","pubTimestamp":1786017602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLX4G8G05:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","IE0002141913.USD","LU0889565916.HKD","LU0320765992.SGD","BK4139","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","IE0009355771.USD","LU0109394709.USD","PRAX","IBRN","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657635318","title":"Viridian Therapeutics Q2 Net Loss Widens as Lumvoa Launch Lifts Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2657635318","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657635318?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:36","pubTimestamp":1786016160,"startTime":"0","endTime":"0","summary":"Viridian Therapeutics Q2 net loss widens as Lumvoa launch lifts costsOverviewU.S. biotech firm's Q2 net loss widened yr/yr as Lumvoa launch drove higher SG&A costsCompany ended Q2 with $981.5 mln in c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430IF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRDN","IBRN","DNTH","MNKD","BK4584","BK4007","OCUL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657331716","title":"Climb Bio Q2 Net Loss Widens on Pipeline Advancement","url":"https://stock-news.laohu8.com/highlight/detail?id=2657331716","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657331716?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:29","pubTimestamp":1786015790,"startTime":"0","endTime":"0","summary":"Climb Bio Q2 net loss widens on pipeline advancementOverviewUS biotechnology firm's Q2 net loss widened yr/yr as operating expenses increasedCompany completed $110 mln private placement, extending cas","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430JV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TYRA","CLYM","IBRN","BK4539","DNTH","ELVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657692633","title":"Scholar Rock Q2 Net Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2657692633","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657692633?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:22","pubTimestamp":1786015339,"startTime":"0","endTime":"0","summary":"Scholar Rock Q2 net loss narrowsOverviewUS biopharmaceutical firm's Q2 net loss narrowed slightly yr/yr with no revenue recordedOperating expenses for Q2 fell, driven by reduced research and developme","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430J6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","BK4584","CMPS","IBRN","BDTX","MNKD","THNR","SRRK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657638693","title":"Scholar Rock Holding Q2 EPS $(0.84) Beats $(0.85) Estimate; Cash Balance Of $492M","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638693","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657638693?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:04","pubTimestamp":1786014281,"startTime":"0","endTime":"0","summary":"Scholar Rock Holding (NASDAQ:SRRK) reported quarterly losses of $(0.84) per share which beat the analyst consensus estimate of $(0.85) by 1.18 percent. This is a 14.29 percent increase over losses of $(0.98) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60987314/scholar-rock-holding-q2-eps-0-84-beats-0-85-estimate-cash-balance-492m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","BK4139","SRRK","THNR"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}]}}